comparemela.com
Home
Live Updates
Keynote 564 - Breaking News
Pages:
Latest Breaking News On - Keynote 564 - Page 1 : comparemela.com
Adjuvant Pembrolizumab Significantly Prolongs OS vs Placebo in ccRCC
Treatment with adjuvant pembrolizumab significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.
United states
Dana farber cancer institute
Bristol myers squibb
Nancy kohlberg
Toni choueiri
Roche genentech
Calithera biosciences
Sanofi aventis
Michaelj hennessy associates
Gilead sciences
Infinity pharmaceuticals
Lank center
Kidney cancer program
Medicine at harvard medical school
Foundation medicine
Navinata health
Scenario 3: A 44-Year-Old Woman With RCC at Intermediate-High Risk for Recurrence
Expert panelists highlight aspects of a final patient scenario, discussing adjuvant treatment strategies in the setting of renal cell carcinoma at intermediate-high risk for recurrence.
Optimizing outcomes
Patients with
Translating evidence
Clinical practice
Year old woman with
Intermediate high risk
Renal cell carcinoma
Kidney cancer
Adjuvant pembrolizumab
Trio therapy
Immune checkpoint inhibitors
Keynote 564
Prosper trial
Prosper study
Combination therapy
Novel therapy
vimarsana © 2020. All Rights Reserved.